New drug combo aims to finish off hidden leukemia cells in high-risk patients

NCT ID NCT07301138

Not yet recruiting Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called BEBT-908 combined with chemotherapy in adults with a rare, high-risk form of acute lymphoblastic leukemia (ALL) who are in remission but still have tiny amounts of cancer cells detectable. The goal is to see if the combo can clear those leftover cells and improve long-term outcomes. About 23 participants will receive the treatment at multiple hospitals in China.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-lymphoblastic leukemia with MEF2D rearrangement Neoplasm, Residual precursor B-cell acute lymphoblastic leukemia Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China

Contact Phone: •••-•••-•••• Email: •••••@•••••